We are thrilled to congratulate the REBLOZYL WW and US Marketing Team from Bristol Myers Squibb on being selected as an ELITE100 Marketing Team! Don’t miss a chance to meet them and all of our other incredible ELITE winners tomorrow on June 18th at 230 FIFTH Rooftop in NYC for our celebration of the pharma industry’s best and brightest: https://lnkd.in/g4nE39eW
PM360 Magazine’s Post
More Relevant Posts
-
🔥 The countdown is on, and the excitement is palpable! Two weeks from now, you will have the opportunity to elevate your game, expand your horizons and, live the ReImagine Pharma Marketing Experience! ✅Explore how AI tools can be implemented in your marketing efforts to maximize resources and deliver effective messages while enhancing targeting capabilities. ✅Discuss how Social Media platforms function as search engines, the advantages and challenges they present, and how marketers can leverage this trend to connect with their target audience. ✅ReImagine the Legal Review Process to streamline the review process, understanding the risk tolerance of your company. Don't miss your chance to be a part of this electrifying journey! 🎊 Apply for one of the last VIP PASSES HERE : https://cvent.me/LNwBOD #ReImaginePharma #PharmaMarketingRevolution #InnovationUnleashed #HealthcareInnovators #MarketingExcellence #FutureOfHealthcare #PharmaIndustry https://lnkd.in/dxQaGUAT
Being able to collaborate with such amazing and talented people is truly an honor. Robert (Bob) Allen our Conference Co-Chair for ReImagine Pharma Marketing on May 21-22 took some time to record this invitation message! We still have a couple of VIP Passes, send me a DM to learn more, or click here to apply: https://cvent.me/LNwBOD Looking forward to seeing you in Long Branch in a couple of weeks.
To view or add a comment, sign in
-
Healthcare and Life Sciences Partner | Pharma R&D | Innovation | Productivity Improvement | Digital Strategy
Kearney's #PractitionersVoices continues with Axel Wiest sharing some of his profound experience with successful transformation in Drug Development, in conversation with our Marc P. Philipp. Listen in to learn about some of the key trends influencing Development Strategy - from IRA to geographic shifts - and how to set the organization up for successful transformation. Check it out on: https://lnkd.in/eEidciRv
Watch our new #PractitionersVoices episode, where I sit with Axel Wiest, Head R&D Strategy & Planning at Bristol Myers Squibb, to talk about the required end-to-end mindset to be successful in drug discovery and development. We clearly need the next level of collaboration across the biopharma value chain to successfully bring new treatments to patients faster! Watch here: https://lnkd.in/eEidciRv
To view or add a comment, sign in
-
-
Watch our new #PractitionersVoices episode, where I sit with Axel Wiest, Head R&D Strategy & Planning at Bristol Myers Squibb, to talk about the required end-to-end mindset to be successful in drug discovery and development. We clearly need the next level of collaboration across the biopharma value chain to successfully bring new treatments to patients faster! Watch here: https://lnkd.in/eEidciRv
To view or add a comment, sign in
-
-
I confess to not knowing the company or the back story, but if you want proof of how proof points can turn a simple narrative into a compelling and powerful one, look no further. Thanks to Alvin for the share.
Katie Porter should make a good President! Listen to how she grilled a big pharma CEO!
To view or add a comment, sign in
-
In business you need to know your numbers. And pretend that you have to check the numbers does not cut it. In the end somebody will show you the real numbers .
Katie Porter should make a good President! Listen to how she grilled a big pharma CEO!
To view or add a comment, sign in
-
This is exactly how we may resolve main pharmaceutical challenges
Katie Porter should make a good President! Listen to how she grilled a big pharma CEO!
To view or add a comment, sign in
-
Wrong academic mindset. If you cut the profit, nobody invests in health companies, the money pivot to anything else “not-so-essencial”, and that company is over, so are the drugs, and the R&D, and everything else. She is applying a “government” solution (that does not depends on profit but taxes) to a private company. Also, not always the problem contains the solution. That is an academic tought, not a CEO’s. That’s why you need innovation, and disruptive mindsets. Always. P.S: does not mean this specific company’s practices are right… I do not have the data she had access to.
Katie Porter should make a good President! Listen to how she grilled a big pharma CEO!
To view or add a comment, sign in
-
After years of underperformance, the pharma industry is seeing a steady pickup in M&A activity. Life Sciences and M&A partner Nicole Daley shares her thoughts on portfolio diversification and additive dealmaking, and on how companies with a sharper focus can be more appealing to investors in the life sciences arena with PharmaVoice. Read more below. #LifeSciences #M&A #Pharma
To view or add a comment, sign in
-
After years of underperformance, the pharma industry is seeing a steady pickup in M&A activity. Life Sciences and M&A partner Nicole Daley shares her thoughts on portfolio diversification and additive dealmaking, and on how companies with a sharper focus can be more appealing to investors in the life sciences arena with PharmaVoice. Read more below. #LifeSciences #M&A #Pharma
Allen & Overy’s Nicole Daley on the rebound in M&A activity in the pharma industry
allenovery.smh.re
To view or add a comment, sign in